Skip to content

Evolution of Cardiovascular Function and Quality of Life in Patients Included in the SCArabée Therapeutic Education Program

A Pilot, Prospective Study Assessing the Evolution of Cardiovascular Function and Quality of Life in Patients With Acute Coronary Syndrome, Included in the SCArabée Therapeutic Education Program

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03669211
Acronym
SCArabée
Enrollment
30
Registered
2018-09-13
Start date
2019-01-07
Completion date
2020-12-15
Last updated
2021-07-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Coronary Syndrome

Keywords

Therapeutic education, Cardiac stress test

Brief summary

Coronary artery disease is defined as a disease of the arteries that vascularize the heart, resulting in myocardial ischemia, i.e. insufficient blood supply to the heart muscle. Eventually, it may be responsible for acute coronary syndrome that includes unstable angina (chest pain) and myocardial infarction (necrosis of the heart muscle). The main cause of this disease is atheroma, and management involves reducing modifiable cardiovascular risk factors (sedentary lifestyle, smoking, obesity, high blood pressure, diabetes, dyslipidemia). Every year, this disease affects more than 120 000 people in France, aging 65 years on average. In this real public health problem, there is a significant discrepancy between the excellence of the management of the acute incident and the inadequacy of the re-adaptive and educational management of the care suites. In fact, it is noted that hospitalization times are short given the progress of myocardial revascularization, associated with a low intra-hospital mortality rate, 3% but the places in rehabilitation programs (Soins de Suite et de Réadaptation or SSR) are too limited (25% of the patients are included in these programs). Physical rehabilitation has proven effective for decades, with robust evidence of decreased recurrence and mortality (-20%). At the Groupe Hospitalier Mutualiste of Grenoble, France, patients are offered two courses of treatment in post-myocardial infarction: * A therapeutic education program: SCarabée, * A rehabilitation program (SSR) The therapeutic education program aims to help the patient identify his needs, acquire knowledge, strengthen his resources and finally develop with him a project to improve his quality of life. SSR offers physical rehabilitation as a treatment for infarction, which improves cardiovascular function, which is assessed by the cardiorespiratory test. Is the Scarabée therapeutic education program is sufficient to help the patient improve his physical abilities? This study aims to answer this question, by setting up a reinforced monitoring of the evolution of the cardiovascular function of the patients included in the SCArabée program, via cardiorespiratory tests. The results of this first pilot study will potentially lead to a second randomized study comparing therapeutic education associated with Adapted Physical Education versus therapeutic education alone for the improvement of cardiorespiratory functions and the quality of life of these patients.

Interventions

DIAGNOSTIC_TESTCardiac stress test

In order to assess the evolution of their cardiorespiratory function, patients will benefit from two cardiac stress test combined with VO2 study, one at inclusion in the study, and the other one 6 months later.

Sponsors

Fondation de l'Avenir
CollaboratorOTHER
Groupe Hospitalier Mutualiste de Grenoble
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Male or female, aged 18 or older * Patient with newly diagnosed or recurring Acute Coronary Syndrome, or presenting a coronary heart disease detected on ischemia test and stented * Patient included in the SCArabée therapeutic education program * Patient assessed stable on the basis of a clinical examination, or exercise test, or ultrasound data * Patient in physical capacity to perform a cardiorespiratory test * Patient giving free, informed and written consent * Patient affiliated to the social security system

Exclusion criteria

* Impossibility to submit to follow-up of the study for geographical social or psychological reasons * Persons referred to in Articles L1121-5 to L1121-8 of the Public Health Code (corresponds to all persons protected): pregnant woman, parturient, nursing mother, person deprived of liberty by judicial or administrative decision, person making the subject of a legal protection measure

Design outcomes

Primary

MeasureTime frameDescription
Assess the evolution of cardiovascular function of patients included in the SCArabée programAt inclusion, and 6 month after inclusionEndpoint : Percentage change in the VO² threshold between the two cardiac stress tests

Secondary

MeasureTime frameDescription
Assess the evolution of cardiac functionAt inclusion, and 6 month after inclusionEndpoint : Left Ventricular Ejection Fraction measured during the two cardiac stress tests
Assess the evolution of perceived level of anxietyAt inclusion, and 6 month after inclusionEndpoint : Score of the Hospital Anxiety and Depression Scale filled by the patient
Assess the evolution of global quality of lifeAt inclusion, and 6 month after inclusionEndpoint : Score of the 12-Item Short Form Health Survey (SF-12) filled by the patient
Assess the evolution of weightAt inclusion, and 6 month after inclusionMeasured during a bioelectrical impedance analysis
Assess the evolution of the patient's physical activityAt inclusion, and 6 month after inclusionEndpoint : Score of the Ricci and Gagnon questionnaire filled by the patient
Assess the evolution of visceral fat massAt inclusion, and 6 month after inclusionMeasured during a bioelectrical impedance analysis
Assess the evolution of muscular massAt inclusion, and 6 month after inclusionMeasured during a bioelectrical impedance analysis
Assess the evolution of Body Mass IndexAt inclusion, and 6 month after inclusion
Assess the evolution of tobacco consumptionAt inclusion, and 6 month after inclusionComparison of the number of cigarettes consumed per day between the month preceeding the Acute Coronary Syndrome event and the 6th month of follow-up
Assess the evolution of fat massAt inclusion, and 6 month after inclusionMeasured during a bioelectrical impedance analysis

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026